Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 10, 2012, Pages 1625-1630

  Jeon, Eun Kyoung ^a   Won, Hye Sung ^b   Ko, Yoon Ho ^b   Lee, In Seok ^a   Hong, Tae Ho ^a   You, Young Kyoung ^a   Lee, Myung Ah ^a  

^a The Catholic University of Korea   (South Korea)

^b Uijeongbu St Mary's Hospital   (South Korea)

Author keywords

Capecitabine; Erlotinib; Gemcitabine; Pancreatic cancer

Indexed keywords

CAPECITABINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84866729833     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1234-y     Document Type: Article

References (19)

1. Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20(15):3270-3275
2. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413
3. Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160-164
4. Cunningham D, Chau I, Stocken DD et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27(33):5513-5518
5. Heinemann V, Quietzsch D, Gieseler F et al (2006) Randomized phase III trial of gemcitabine plus Cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24(24):3946-3952
6. Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25(16): 2212-2217
7. Hess V, Salzberg M, Borner M et al (2003) Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 21(1):66-68
8. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
9. Kindler HL, Niedzwiecki D, Hollis D et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28(22):3617-3622
10. Louvet C, Labianca R, Hannel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15): 3509-3516
11. Matano E, Taqliaferri P, Libroia A et al (2000) Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer 82(11):1772-1775
12. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960-1966
13. Oettle H, Richards D, Ramanathan RK et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16(10):1639-1645
14. Park BB, Park JO, Lee HR et al (2007) A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adeno-carcinoma. Cancer Chemother Pharmacol 60(4):489-494
15. Philip PA, Benedetti J. Corless CL et al (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28(22):3605-3610
16. Rauch DP, Maurer CA, Aebi S et al (2001) Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology 60(1):43-48
17. Ren Q, Kao V, Grem JL (1998) Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxy-uridine in HT-29 colon cancer cells. Clin Cancer Res 4(11): 2811-2818
18. Schilsky RL, Bertucci D, Vogelzang NJ et al (2002) Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 20(2):582-587
19. Xie DR, Yang Q, Chen DL et al (2010) Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol 40(5):432-441